防治成人呼吸窘迫综合征的人工重组肺泡表面活性剂研制III.模型动物预防试验

ARTIFICIAL RECONSTITUTED PULMONAY SURFACTANT USED FOR PREVENTION AND TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME III. PREVENTION IN ANIMAL MODEL

摘要: 人工重组肺泡表面活性剂（ＡＰＳ）是基于成人呼吸窘迫综合征（ＡＲＤＳ）发病中存在的肺泡表面活性剂缺乏和过量自由基引起肺损伤两种主要发病因素设计研制的。内毒素致ＡＲＤＳ大鼠的预防给药试验结果表明，ＡＰＳ能显著降低动物死亡率（46.47%→16.17%）和肺水肿程度（Ｗ／Ｄ从5.55→4.84）。同时，肺灌洗液的表面性能也有明显改善（平衡表面张力从61.86→47.02ｍＮ·ｍ^-1，正常43.94ｍＮ·ｍ^-1；最小表面张力从30.41→7.16ｍＮ·ｍ^-1，正常3.49ｍＮ·ｍ^-1）。动物初步预防试验的结果支持ＡＲＤＳ防治药物设计依据。

Abstract: Based on two major factors resulted in adult respiratory distress syndrome (ARDS), lack of pulmonary surfactant and damage of free radicals, an artificial reconstituted pulmonary surfactant (APS) was prepared. The results of prevention of ARDS in ARDS rats showed that APS reduced the mortality of animal model significantly (from 46.47% to 16.17%) and the ratio of wet/dry lung weight (from 5.55 to 4.84). The surface properties of lung lavage of treated animals were improved effectively balancing surface tension from 61.86 mN·m ^-1 to 47.02 mN·m^-1, (normal 43.94 mN·m^-1 ), minimal surface tension from 30.41 mN·m^-1 to 7.16 mN·m^-1 (normal 3.49 mN·m^-1). These results indicate that the APS preparation showed better effect on prevention of ARDS in rats.